Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus
Abstract
Background: Glycated haemoglobin (HbA1c) is an indicator of average blood glucose concentrations over the preceding 3 months, is simpler to perform than either a fasting glucose or glucose tolerance test and is associated with a worse prognosis in some clinical settings. However, its relationship to survival in patients with suspected heart failure has not been studied. Methods: Patients referred to a community-based heart failure clinic with suspected heart failure had a comprehensive assessment including the measurement of HbA1c. For this analysis, patients with DM or who started diabetic medication in the subsequent 12 months, which might influence HbA1c, were excluded. Findings: Of 970 non-diabetic patients referred between 2001 and 2004, the median age was 72 years (range 25 to 96 years), 56% were men, 45% had left ventricular ejection fraction (LVEF) ⩽45%, and 50% had an HbA1c >6% (upper reference limit). Among patients with LVEF ⩽45%, there was an abrupt increase in mortality in those with an HbA1c >6.7% (n = 68) compared with those with HbA1c ⩽6.7% (n = 368) (hazard ratio (HR): 2.4, p45% (HR 1.44, p = 0.36 after adjustment). Interpretation: The abrupt increase in mortality with HbA1c may make it a useful risk stratification tool in non-diabetic patients with LVEF ⩽45% which could help improve clinical management.Keywords
This publication has 38 references indexed in Scilit:
- Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failureHeart, 2008
- Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year studyHeart, 2008
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2008
- Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose ToleranceCirculation, 2007
- A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and ageHeart, 2007
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international surveyThe Lancet, 2002
- Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart FailureCirculation, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992